Characterization of two new high-grade B-cell lymphoma cell lines with MYC and BCL2 rearrangements that are suitable for in vitro drug sensitivity studies

References

• Swerdlow SH, Campo E, Harris NL, et al. who classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon: IARC; 2017.
   Google Scholar
• Dang CV, O'Donnell KA, Zeller KI, et al. The c-Myc target gene network. Semin Cancer Biol. 2006;16:253–264.
   PubMed Web of Science ®Google Scholar
• Li S, Weiss VL, Wang XJ, et al. High-grade B-cell lymphoma with MYC rearrangement and without BCL2 and BCL6 rearrangements is associated with high P53 expression and a poor prognosis. Am J Surg Pathol. 2016;40:253–261.
   PubMed Web of Science ®Google Scholar
• Epperla N, Maddocks KJ, Salhab M, et al. C-MYC–positive relapsed and refractory, diffuse large B-cell lymphoma: impact of additional ‘hits’ and outcomes with subsequent therapy. Cancer. 2017;123:4411–4418.
   PubMed Web of Science ®Google Scholar
• Czabotar PE, Lessene G, Strasser A, et al. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014;15:49–63.
   PubMed Web of Science ®Google Scholar
• Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. JCO. 2012;30:3452–3459.
   PubMed Web of Science ®Google Scholar
• Green TM, Young KH, Visco C, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large b-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. JCO. 2012;30:3460–3467.
   PubMed Web of Science ®Google Scholar
• Basso K, Dalla-Favera R. Roles of BCL6 in normal and transformed germinal center B cells. Immunol Rev. 2012;247:172–183.
   PubMed Web of Science ®Google Scholar
• Anderson MA, Tsui A, Wall M, et al. Current challenges and novel treatment strategies in double hit lymphomas. Ther Adv Hematol. 2016;7:52–64.
   PubMed Web of Science ®Google Scholar
• Viardot A, Goebeler M-E, Hess G, et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood. 2016;127:1410–1416.
   PubMed Web of Science ®Google Scholar
• Locke FL, Neelapu SS, Bartlett NL, et al. Phase 1 results of ZUMA-1: a multicenter study of kte-c19 anti-cd19 car t cell therapy in refractory aggressive lymphoma. Mol Ther. 2017;25:285–295.
   PubMed Web of Science ®Google Scholar
• Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202–208.
   PubMed Web of Science ®Google Scholar
• Wilson WH, O'Connor OA, Czuczman MS, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010;11:1149–1159.
   PubMed Web of Science ®Google Scholar
• Trabucco SE, Gerstein RM, Evens AM, et al. Inhibition of bromodomain proteins for the treatment of human diffuse large b-cell lymphoma. Clin Cancer Res. 2015;21:113–122.
   PubMed Web of Science ®Google Scholar
• Drexler HG, Eberth S, Nagel S, et al. Malignant hematopoietic cell lines: in vitro models for double-hit B-cell lymphomas. Leuk Lymph. 2016;57:1015–1020.
   PubMed Web of Science ®Google Scholar
• McGowan-Jordan J, Simons A, Schmid M. ISCN: an international system for human cytogenomic nomenclature (2016). Basel: Karger; 2016.
   Google Scholar
• Duhoux FP, Ameye G, Lambot V, et al. Refinement of 1p36 alterations not involving PRDM16 in myeloid and lymphoid malignancies. PLoS One. 2011;6:1–9.
   Web of Science ®Google Scholar
• Ryan JL, Fan H, Glaser SL, et al. Epstein-Barr virus quantitation by real-time PCR targeting multiple gene segments: a novel approach to screen for the virus in paraffin-embedded tissue and plasma. J Mol Diagn. 2004;6:378–385.
   PubMed Web of Science ®Google Scholar
• Giudicelli V, Brochet X, Lefranc M-P. IMGT/V-QUEST: IMGT standardized analysis of the immunoglobulin (IG) and T cell receptor (TR) nucleotide sequences. Cold Spring Harb Protoc. 2011;2011:695–715.
   PubMedGoogle Scholar
• Dubois S, Viailly PJ, Mareschal S, et al. Next-generation sequencing in diffuse large B-cell lymphoma highlights molecular divergence and therapeutic opportunities: a LYSA study. Clin Cancer Res. 2016;22:2919–2928.
   PubMed Web of Science ®Google Scholar
• Stoner CS, Pearson GD, Koç A, et al. Effect of thioredoxin deletion and p53 cysteine replacement on human p53 activity in wild-type and thioredoxin reductase null yeast. Biochemistry. 2009;48:9156–9169.
   PubMed Web of Science ®Google Scholar
• Schuetz JM, Johnson NA, Morin RD, et al. BCL2 mutations in diffuse large B-cell lymphoma. Leukemia. 2012;26:1383–1390.
   PubMed Web of Science ®Google Scholar
• White MTG, Zehnbauer PD, Zutter MDMM, et al. Lack of expression of surface immunoglobulin light chains in b-cell non-hodgkin lymphomas. Am J Clin Pathol. 2000;113:399–405.
   PubMed Web of Science ®Google Scholar
• Evans AG, Spence JM, Spence SA, et al. Diffuse large b-cell lymphoma lacking surface b-cell receptor expression are germinal center b-cell (GCB)-type and lack evidence of known downstream activating mutations. Blood. 2015;126:1453.
   Web of Science ®Google Scholar
• Gebauer N, Bernard V, Gebauer W, et al. TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations. Leuk Lymph. 2015;56:179–185.
   PubMed Web of Science ®Google Scholar
• Bouska A, Bi C, Lone W, et al. Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets. Blood. 2017;130:1819–1831.
   PubMed Web of Science ®Google Scholar
• Kotsiou E, Okosun J, Besley C, et al. TNFRSF14 aberrations in follicular lymphoma increase clinically significant allogeneic T-cell responses. Blood. 2016;128:72–81.
   PubMed Web of Science ®Google Scholar
• Cheung K-JJ, Johnson NA, Affleck JG, et al. Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis. Cancer Res. 2010;70:9166–9174.
   PubMed Web of Science ®Google Scholar
• Pastore A, Jurinovic V, Kridel R, et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015;16:1111–1122.
   PubMed Web of Science ®Google Scholar
• Morin RD, Mendez-lago M, Mungall AJ, et al. Frequent mutation of histone modifying genes in non-Hodgkin lymphoma. Nature. 2011;476:298–303.
   PubMed Web of Science ®Google Scholar
• Fresquet V, Rieger M, Carolis C, et al. Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma. Blood. 2014;123:4111–4119.
   PubMed Web of Science ®Google Scholar